Comparative Pharmacology
Head-to-head clinical analysis: BEVESPI AEROSPHERE versus STIOLTO RESPIMAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEVESPI AEROSPHERE versus STIOLTO RESPIMAT.
BEVESPI AEROSPHERE vs STIOLTO RESPIMAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BEVESPI AEROSPHERE is a combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA). Glycopyrrolate inhibits acetylcholine at M3 muscarinic receptors in bronchial smooth muscle, leading to bronchodilation. Formoterol stimulates beta2-adrenergic receptors, increasing cyclic AMP and relaxing bronchial smooth muscle.
Dual bronchodilator: tiotropium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors at smooth muscle, causing bronchodilation; olodaterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, relaxing airway smooth muscle.
Two inhalations (glycopyrrolate 18 mcg / formoterol fumarate 9.6 mcg per inhalation) twice daily, administered orally via inhalation.
2 inhalations (2.5 mcg tiotropium/2.5 mcg olodaterol per inhalation) once daily via Respimat inhaler.
None Documented
None Documented
Glycopyrrolate: terminal elimination half-life 3.2 to 4.1 hours after inhalation; formoterol: terminal elimination half-life approximately 10 hours after inhalation. Context: Steady-state achieved within 2 to 3 days.
Tiotropium: 5-6 days (terminal). Olodaterol: 17-19 hours (terminal). Clinically, once-daily dosing maintains therapeutic levels.
Renal: 15% to 30% as unchanged drug after intravenous administration for glycopyrrolate; fecal: 65% to 80% as unchanged drug after oral administration for glycopyrrolate. For formoterol, renal: 10% to 20% as unchanged drug; bile/fecal: 60% to 70%.
Tiotropium: 14% renal unchanged, remainder as non-renally eliminated metabolites (biliary/fecal). Olodaterol: <1% renal unchanged, 84% fecal as metabolites, 16% renal as metabolites.
Category C
Category C
LAMA/LABA Combination
LAMA/LABA Combination